DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Erwinase Study in Patients With Acute Lymphoblastic Leukemia

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia

Intervention: Erwinase (Drug)

Phase: N/A

Status: Completed

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Robert J. Wells, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center


The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase«) as a replacement for patients who are allergic to E. coli L-asparaginase or Pegylated E. coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma. This trial was part of a multi institutional effort by the drug company to make Erwinase available for use.

Clinical Details

Official title: Erwinia L-Asparaginase (Erwinase) Study in Patients With Acute Lymphoblastic Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Participant Toxicity Data

Number of Participants Treated With Erwinase as a Replacement for E.Coli L-asparaginase or Pegylated E.Coli L-asparaginase as Part of the Treatment for Acute Lymphoblastic Leukemia (ALL) or T or B Cell Lymphoma

Detailed description: The Study Drug: Erwinia L-Asparaginase helps stop the growth of cancer cells by blocking the nutrients that cancer cells needed to survive. Study Visits: Erwinia L-Asparaginase will be given either outpatient or inpatient, depending upon your condition. If you are allergic to E. Coli Asparaginase or Pegylated Asparaginase, you will be given 6 doses every other day. You will receive Erwinia L-Asparaginase as an injection through a needle in your vein, under the skin, or in your muscle, as directed by your study doctor. You will be monitored closely by your nurse and your doctor before, during, and after receiving the drug for any side effects. If you develop a severe allergy to Erwinia L-Asparaginase, you may not receive any more asparaginase therapy. The length of study will be based upon on the ALL treatment you are currently receiving. Your doctor will discuss the details of your treatment schedule with you. This is an investigational study. Erwinia L-Asparaginase is not FDA approved. The FDA allows patients with acute lymphoblastic leukemia who have an allergic reaction to the U. S.-approved L-asparaginases to receive Erwinia L-Asparaginase. Up to 35 patients will take part in this study at The University of Texas (UT) MD Anderson Cancer Center.


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Age: no restrictions 2. Patient must give written informed consent to receive Erwinase® under Investigational New Drug (IND) 290. 3. Patient must be treated for Acute Lymphoblastic Leukemia 4. Patient with either T or B cell lymphoma being treated with Asparaginase. 5. Patient must have either systemic hypersensitivity reactions to native (Elspar®) or pegylated (Oncaspar®) E. coli L-Asparaginase. This includes patients with generalized rash with or without anaphylactic symptoms, but not those with only local pain or redness at the site of injection. 6. Patient with previously documented local or systemic reactions to E. coli derived L-Asparaginase. 7. Patients who are on Elspar® (including those enrolled in a clinical trial randomized to Elspar®) and where Elspar® is not available. Exclusion Criteria: 1. Previous allergic reaction to Erwinia L-Asparaginase (Erwinase ®) 2. Previous acute pancreatitis 3. Pregnant or lactating woman

Locations and Contacts

UT MD Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information

The University of Texas MD Anderson Cancer Center Official Website

Starting date: May 2007
Last updated: September 4, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015